Related Experiment Video
Updated: Oct 7, 2025
08:54
Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
19.2K
Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective
Frederic Lamoth1, Russell E Lewis2, Dimitrios P Kontoyiannis3
1Infectious Diseases Service and Institute of Microbiology, University Hospital of Lausanne and Lausanne University, Lausanne, Switzerland.
Summary
New antifungal drugs are in development to combat challenging invasive fungal infections (IFIs). These novel agents show promise against resistant pathogens but have limitations against certain molds.
Area of Science:
- Infectious Diseases
- Mycology
- Pharmacology
Background:
- Treatment of invasive fungal infections (IFIs) is difficult due to current antifungal limitations like toxicity and drug resistance.
- Emerging resistant fungal strains necessitate the development of new antifungal therapies.
Purpose of the Study:
- To review emerging antifungal agents for invasive fungal infections.
- To assess the potential role of new antifungals in clinical practice.
Main Methods:
- Review of compounds in phase II or III clinical trials.
- Analysis of novel antifungal mechanisms and properties.
Main Results:
- New drugs (rezafungin, ibrexafungerp, olorofim, fosmanogepix) are advancing in clinical development.
- These agents may offer improved options for azole-resistant and multidrug-resistant fungal infections.
- Limited activity against Mucorales and some Fusarium species remains a significant challenge.
Conclusions:
- Novel antifungal agents show potential to expand treatment options for specific IFIs.
- Further data are needed, especially for heavily immunosuppressed patients.
- Unmet needs persist for treating infections caused by certain molds.
Related Concept Videos
01:28Fungal Phylum Microsporidia
166
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
166
01:28Antimicrobial Effectiveness
293
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
293
01:11Clinical Trials: Overview
3.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.7K
01:16Therapeutic Drug Monitoring: Overview and Classification
16
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
16